Oral estramustine and oral etoposide for hormone-refractory prostate cancer

By Dimopoulos M.A.   Panopoulos C.   Bamia C.   Deliveliotis C.   Alivizatos G.   Pantazopoulos D.   Constantinidis C.   Kostakopoulos A.   Kastriotis I.   Zervas A.   Aravantinos G.   Dimopoulos C.  

Urology, Vol. 50, Iss. 5, 1997-11 ,pp. : 754-758

Elsevier

Access to resources Recommend Favorite

Chemotherapy for the Treatment of Hormone-Refractory Prostate Cancer

By Petrylak D.P.  

European Urology Supplements, Vol. 1, Iss. 2, 2002-05 ,pp. : 15-23

Elsevier

Access to resources Recommend Favorite

Phase I trial of weekly paclitaxel plus oral estramustine phosphate in patients with hormone-refractory prostate cancer

By Haas N.   Roth B.   Garay C.   Yeslow G.   Entmacher M.   Weinstein A.   Rogatko A.   Babb J.   Minnitti C.   Flinker D.   Gillon T.   Hudes G.  

Urology, Vol. 58, Iss. 1, 2001-07 ,pp. : 59-64

Elsevier

Access to resources Recommend Favorite

A phase II trial of oral estramustine and oral etoposide in hormone refractory prostate cancer

By Pienta K.J.   Redman B.G.   Bandekar R.   Strawderman M.   Cease K.   Esper P.S.   Naik H.   Smith D.C.  

Urology, Vol. 50, Iss. 3, 1997-09 ,pp. : 401-407

Elsevier

Access to resources Recommend Favorite

The combination of estramustine and mitoxantrone in hormone-refractory prostate cancer: a phase II feasibility study conducted by the Hellenic Cooperative Oncology Group

By Samelis G.F.   Skarlos D.   Bafaloukos D.   Kosmidis P.   Anagnostopoulos A.   Aravantinos G.   Dimopoulos M.A.  

Urology, Vol. 61, Iss. 6, 2003-06 ,pp. : 1211-1215

Elsevier

Access to resources Recommend Favorite